If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...

Shares of Amgen (AMGN) fell on Tuesday after the biotech company reported results for a phase 2 study of its obesity injection, which fell short of efficacy expectations, Mizuho Securities said. Amgen ...

In a recent budget meeting the Tennessee Department of Finance and Administration’s Division of TennCare made some requests ...

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by ...

People who talk in their sleep may be at greater risk of stroke, according to a study of 8,001 Chinese adults. The risk was ...

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

GLP-1RA dispensing has increased from 2022 and 2023, whereas metabolic bariatric surgery has decreased among individuals with obesity.